Send Inquiry

Request To Call Back

Everolimus Eluting Stent

Price 200 USD ($)/ Piece

Get a Price/Quote

MOQ : 1 Piece

Everolimus Eluting Stent Specification

Usage Type
Single Use

Function
Restores blood flow, prevents arterial re-narrowing

Shelf Life
2-3 years (unopened, as per manufacturers guidelines)

Features
Biocompatible, Flexible, Thin Struts, Controlled Drug Release

Instruments Type
Interventional Cardiology Device

Accuracy
High Precision Delivery

Storage Instructions
Store in a cool, dry place; avoid direct sunlight

Measurement Range
Stent Diameter: 2.00-4.00 mm, Length: 8-38 mm

Equipment Type
Everolimus Eluting Stent

Material
Cobalt Chromium Alloy

Condition
New

Technology
Drug Eluting Stent (DES) with Everolimus Coating

Portable
Yes

Wall Mounted
No

Real-Time Operation
Yes

Noise Level
Silent

Operating Type
Manual Placement with Catheter Assistance

Use
Coronary Artery Disease Treatment

Dimension (L*W*H)
Varies by stent size (Typically 8-38 mm length, 2.00-4.00 mm diameter)

Weight
Lightweight (Approx. few milligrams)

Color
Metallic Silver

Radiopacity
Radiopaque markers for visibility under fluoroscopy

Delivery System
Premounted on balloon catheter

Expansion
Balloon expandable

Sterilization Method
Ethylene oxide or gamma sterilized

Coating Material
Everolimus (anti-proliferative drug)

Application Area
Coronary arteries

Flexibility
High flexibility for ease of vessel navigation

Balloon Compatibility
Compatible with standard PTCA balloon catheters

About Everolimus Eluting Stent

Advin Health Care Everolimus Eluting Stent is designed for advanced coronary interventions with controlled drug release to minimize restenosis and support long-term vessel healing. It delivers excellent flexibility, precise placement, and reliable clinical outcomes.

Key Features:

Controlled everolimus drug release for reduced restenosis

Superior flexibility and deliverability

High radial strength for optimal vessel support

Biocompatible coating for enhanced healing response

Smooth surface for excellent trackability

Certifications:

CE, ISO 13485, ISO 9001 Certified

Product Keywords:

Everolimus Eluting Stent, Drug Eluting Stent, Coronary Stent, DES Stent, Cardiovascular Stent

, , , , -

Stent liberador de everolimus, stent liberador de frmacos, stent coronario, stent DES, stent cardiovascular

Stent lution d'vrolimus, stent lution de mdicament, stent coronaire, stent DES, stent cardiovasculaire

Advanced Drug-Eluting Technology

The stent leverages everolimus, a proven anti-proliferative drug, to reduce the risk of restenosis by inhibiting unintended tissue growth. Its carefully engineered thin struts and biocompatible coating allow for controlled and sustained drug release, optimizing patient outcomes after coronary artery interventions.

Precision and Compatibility

Equipped with radiopaque markers, the stent provides excellent visibility under fluoroscopy for accurate positioning. The high flexibility and compatibility with standard PTCA balloon catheters simplify navigation through complex vascular paths, allowing for dependable and safe manual placement by trained cardiologists.

Quality, Safety, and Convenience

The Everolimus Eluting Stent is sterilized via ethylene oxide or gamma methods, ensuring patient safety. Its robust shelf life of 2-3 years (when stored appropriately) and single-use design prevent contamination, making it ideal for hospitals and clinics. Lightweight and portable, it's suitable for diverse clinical settings across India and worldwide.

FAQ's of Everolimus Eluting Stent:

Q: How is the Everolimus Eluting Stent placed in the coronary artery?

A: The stent is premounted on a balloon catheter and manually delivered to the blocked coronary artery using catheter assistance. Radiopaque markers facilitate visibility, allowing precise positioning under fluoroscopy. Once in place, the balloon is inflated to expand the stent against the artery wall, securing it and restoring blood flow.

Q: What benefits does the everolimus drug coating provide?

A: Everolimus, an anti-proliferative drug, helps prevent restenosis (re-narrowing) of the treated artery by inhibiting excessive cell growth at the stent site, which significantly improves long-term vessel patency and patient outcomes.

Q: When should this stent be used for a patient?

A: The Everolimus Eluting Stent is indicated for patients diagnosed with coronary artery disease where vessel narrowing or blockage requires intervention to restore adequate blood flow. The procedure is determined by a cardiologist following thorough patient assessment.

Q: Where can this stent be applied in the body?

A: This stent is specifically designed for use in the coronary arteries, which supply blood to the heart muscle. It is not intended for other vascular territories.

Q: What is the process for preparing and using the stent?

A: Prior to use, the packaged stent should be stored in a cool, dry place out of direct sunlight and checked for sterility. During the procedure, the physician guides the catheterized stent to the target artery, inflates the balloon to expand the stent, and then withdraws the delivery system, leaving the stent implanted.

Q: How long does the stent remain effective after placement?

A: Once implanted, the stent offers permanent scaffolding. The everolimus drug is released over a controlled period, typically several weeks, reducing the chance of restenosis. Effectiveness is maximized with proper patient follow-up and medication adherence.

Q: What are the key advantages of this stent's design?

A: Key benefits include high flexibility for navigating intricate vessels, biocompatibility, thin strut construction for minimal vessel trauma, high precision delivery, and compatibility with standard PTCA balloon catheters. Controlled drug release and robust sterilization ensure patient safety and effective treatment.

Tell us about your requirement